FDA-Approved Drugs: What Does China’s Growing Role Mean?

What Does the New Drug-Manufacturing Analysis Show?

The analysis examines manufacturing arrangements recorded in 2026 for products approved during 2020–2025. GlobalData reports that the share involving Chinese facilities rose from approximately 1.8% for the earlier three-year period to an average of 6.7% for the later period. Ten products approved in 2023 involved manufacturing in China. These figures concern product counts, rather than prescription volumes or the proportion of each medicine manufactured there. [GlobalData analysis](https://www.globaldata.com/media/pharma/china-expands-role-in-manufacturing-new-fda-approved-drugs-says-globaldata/).

For patients, interpreting the denominator matters: the announcement covers innovator medicines and biosimilars, rather than every drug sold in the United States. It also does not establish that a product's entire manufacturing process occurs in one country. The findings therefore describe a shift in production networks, without demonstrating a corresponding change in clinical outcomes.

How Does the FDA Assess Medicines Manufactured Abroad?

The FDA states that imported medicines must satisfy U.S. requirements covering approval where applicable, labeling and manufacturing quality. Location alone does not establish whether a particular medicine meets those requirements; assessment depends on the product and its manufacturing operations. [FDA import requirements](https://www.fda.gov/drugs/human-drug-imports/general-requirements-importing-human-drugs).

Current good manufacturing practice requirements address raw materials, equipment, production controls, laboratory testing and investigation of quality problems. The FDA inspects facilities worldwide, including sites producing active ingredients and finished medicines. Testing a sample of the finished batch is only one safeguard: reliable processes must build quality into production throughout. [FDA manufacturing-quality overview](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp).

Manufacturing changes also require scientific evaluation. For biological medicines, FDA guidance describes comparing the product before and after a process change to assess potential effects on quality, safety and effectiveness. A manufacturer's ability to demonstrate comparability is therefore central to evaluating a change; a new production arrangement does not by itself establish that a medicine performs differently. [FDA biological-product comparability guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q5e-comparability-biotechnologicalbiological-products-subject-changes-their-manufacturing-process).

Could Expanded Manufacturing Improve Access to Treatment?

Supply depends on usable capacity, dependable production and access to ingredients. The FDA explains that when one manufacturer encounters problems, other suppliers may struggle to increase output quickly. Alternative production lines or ingredient sources can also require regulatory review. The practical implication is that additional qualified capacity may help, but counting manufacturing locations alone cannot establish how reliably patients will receive treatment. [FDA drug-shortage questions and answers](https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages).

Biosimilars offer another route to improved access. These biological medicines must closely match an approved reference product without differences that meaningfully affect clinical safety or effectiveness. The FDA says their availability can expand treatment options and potentially reduce costs through competition. Manufacturing a medicine in a particular country, however, does not make it a biosimilar or establish that patients will pay less. Those conclusions require product-specific regulatory and pricing evidence. [FDA biosimilar overview](https://www.fda.gov/drugs/biosimilars/overview-health-care-professionals).